RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that interim clinical data from the Company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida.
The WORLDSymposium program includes two platform presentations from clinical trials of Sangamo's zinc finger nuclease (ZFN)-mediated in vivo genome editing product candidates, SB-318 and SB-913, which are being evaluated for the treatment of mucopolysaccharidosis type I (MPS I) and type II (MPS II), respectively:
- "CHAMPIONS: A Phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)"
Presenter: Joseph Muenzer, M.D., Ph.D., University of North Carolina School of Medicine
February 7th, 2019 at 11:00 a.m. Eastern Time
- "EMPOWERS: A Phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler Syndrome)"
Presenter: Paul Harmatz, MD, UCSF Benioff Children's Hospital Oakland
February 7th, 2019 at 11:15 a.m. Eastern Time
The SB-913 (MPS II) presentation is expected to include interim data on safety and biochemical measurements at up to 24 weeks from six subjects enrolled in the three dose cohorts of the CHAMPIONS Study. The SB-318 (MPS I) presentation is expected to describe the scientific rationale for SB-318, the clinical trial design, and preliminary safety and biochemical measurements at up to four weeks from the first three patients enrolled in the EMPOWERS Study.
Sangamo expects to provide additional SB-913 and SB-318 updates in 2019 as data accumulate and mature in these clinical development programs.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to presenting at the WORLDSymposium annual conference and the types of data expected to be disclosed at the WORLDSymposium. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the timing and success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation, enrollment and completion of clinical trials, including the CHAMPIONS study and the EMPOWERS study, whether the final results from the EMPOWERS study and CHAMPIONS study will validate and support the interim results and the overall safety and efficacy of SB-318 and SB-913, respectively, Sangamo's reliance on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
SOURCE Sangamo Therapeutics, Inc.